AU2008310713B2 - Cytomegalovirus vaccines and methods of production - Google Patents

Cytomegalovirus vaccines and methods of production Download PDF

Info

Publication number
AU2008310713B2
AU2008310713B2 AU2008310713A AU2008310713A AU2008310713B2 AU 2008310713 B2 AU2008310713 B2 AU 2008310713B2 AU 2008310713 A AU2008310713 A AU 2008310713A AU 2008310713 A AU2008310713 A AU 2008310713A AU 2008310713 B2 AU2008310713 B2 AU 2008310713B2
Authority
AU
Australia
Prior art keywords
cmv
cells
cell
vaccine
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008310713A
Other languages
English (en)
Other versions
AU2008310713A1 (en
Inventor
Thomas Shenk
Dai Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of AU2008310713A1 publication Critical patent/AU2008310713A1/en
Application granted granted Critical
Publication of AU2008310713B2 publication Critical patent/AU2008310713B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2008310713A 2007-10-10 2008-10-10 Cytomegalovirus vaccines and methods of production Ceased AU2008310713B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99842607P 2007-10-10 2007-10-10
US60/998,426 2007-10-10
PCT/US2008/079494 WO2009049138A1 (en) 2007-10-10 2008-10-10 Cytomegalovirus vaccines and methods of production

Publications (2)

Publication Number Publication Date
AU2008310713A1 AU2008310713A1 (en) 2009-04-16
AU2008310713B2 true AU2008310713B2 (en) 2012-06-14

Family

ID=40549581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008310713A Ceased AU2008310713B2 (en) 2007-10-10 2008-10-10 Cytomegalovirus vaccines and methods of production

Country Status (15)

Country Link
US (2) US9439960B2 (enExample)
EP (1) EP2200645B1 (enExample)
JP (1) JP5409638B2 (enExample)
KR (1) KR20100084627A (enExample)
CN (1) CN101820906B (enExample)
AU (1) AU2008310713B2 (enExample)
BR (1) BRPI0818656A2 (enExample)
CA (1) CA2701727C (enExample)
IL (1) IL204850A0 (enExample)
MX (1) MX2010003713A (enExample)
NZ (1) NZ584459A (enExample)
RU (1) RU2491340C2 (enExample)
SG (1) SG185291A1 (enExample)
WO (1) WO2009049138A1 (enExample)
ZA (1) ZA201002216B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP2831285B1 (en) * 2012-03-27 2019-10-30 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
MX378747B (es) 2012-07-06 2025-03-10 Glaxosmithkline Biologicals S A Star Complejos de proteínas de citomegalovirus.
AU2013293570B2 (en) 2012-07-27 2019-05-23 City Of Hope An MVA vaccine for delivery of a UL128 complex and preventing CMV infection
US9395369B2 (en) 2012-10-19 2016-07-19 Regents Of The University Of Minnesota Guinea pig cytomegalovirus (CIDMTR strain)
CN103937871B (zh) * 2013-01-23 2019-07-23 上海市东方医院 Srrp35基因和表达产物在癌症诊断与治疗中的应用
US20160289303A1 (en) * 2013-11-15 2016-10-06 President And Fellows Of Harvard College Methods and compositions for the treatment of hcmv
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3601543A4 (en) * 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS
CA3060019A1 (en) * 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
WO2019089410A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064394A1 (en) * 2003-07-25 2005-03-24 Fenyong Liu Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
US4058598A (en) 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US6471965B1 (en) 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064394A1 (en) * 2003-07-25 2005-03-24 Fenyong Liu Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors

Also Published As

Publication number Publication date
RU2491340C2 (ru) 2013-08-27
US20170014504A1 (en) 2017-01-19
KR20100084627A (ko) 2010-07-27
BRPI0818656A2 (pt) 2015-04-14
EP2200645A4 (en) 2012-07-11
JP2011500592A (ja) 2011-01-06
CN101820906A (zh) 2010-09-01
EP2200645A1 (en) 2010-06-30
CA2701727C (en) 2016-12-13
CN101820906B (zh) 2015-04-22
US10300130B2 (en) 2019-05-28
NZ584459A (en) 2012-06-29
MX2010003713A (es) 2010-08-02
US9439960B2 (en) 2016-09-13
US20100285059A1 (en) 2010-11-11
IL204850A0 (en) 2010-11-30
WO2009049138A1 (en) 2009-04-16
ZA201002216B (en) 2011-06-29
SG185291A1 (en) 2012-11-29
JP5409638B2 (ja) 2014-02-05
CA2701727A1 (en) 2009-04-16
AU2008310713A1 (en) 2009-04-16
RU2010117741A (ru) 2011-11-20
EP2200645B1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
AU2008310713B2 (en) Cytomegalovirus vaccines and methods of production
JP5926804B2 (ja) Ｃｍｖ用ワクチンとしての条件付き複製サイトメガロウイルス
Stevenson et al. Immune control of mammalian gamma-herpesviruses: lessons from murid herpesvirus-4
US20130045230A1 (en) Composition containing hcmv particles
Gray Simian varicella in old world monkeys
US20130195918A1 (en) Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof
Polz-Dacewicz et al. Cytomegalovirus (CMV)–a new prospect for prevention
Morgan Department of Pathology & Microbiology University of Bristol Medical School Bristol, BS8 1TD, UK
HK1240107A (en) A conditional replicating cytomegalovirus as a vaccine for cmv
HK1240107B (en) A conditional replicating cytomegalovirus as a vaccine for cmv
HK1194283B (en) A conditional replicating cytomegalovirus as a vaccine for cmv
HK1194283A (en) A conditional replicating cytomegalovirus as a vaccine for cmv

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired